Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Ticagrelor is an adenosine triphosphate analog and acts as a P2Y1 receptor inhibitor similar to ticlopidine, inhibiting platelet aggregation. It is used in patients with a history of myocardial infarction or acute coronary syndrome to prevent thromboembolism. Oral administration.
At the date of the last update we found no published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make passage into breast milk in clinically significant quantities very unlikely.
If administered during breastfeeding, it is advisable to monitor the appearance of bruising or bleeding in the infant.
Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.